Erratum: Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo (Developmental Neurobiology DOI: 10.1002/dneu.20360);Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo

Developmental Neurobiology

Volumn 67, Issue 7, 2007, Pages 884-894

  Shi, ZhiHua ^a   Birman, Elena ^a   Saragovi, H Uri ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Glaucoma; Neuroprotection; Neurotrophin; Ocular hypertension; Receptor; Retina

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; NERVE GROWTH FACTOR; NEUROTROPHIN; P75 ANTAGONIST; PEPTIDOMIMETIC D3; PROTEIN P75; PROTEIN TYROSINE KINASE A; TRKA RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLAUCOMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL;

EID: 34447562933     PISSN: 19328451     EISSN: 1932846X     Source Type: Journal    
DOI: 10.1002/dneu.20565     Document Type: Erratum

References (45)

1. Atkinson J, Panni MK, Lund RD. 1999. Effects of neurotrophins on embryonic retinal outgrowth. Brain Res Dev Brain Res 112:173-180.
2. Barbacid M. 1994. The Trk family of neurotrophin receptors. J Neurobiol 25:1386-1403.
3. Bruno MA, Clarke PB, Seltzer A, Quirion R, Burgess K, Cuello AC, Saragovi HU. 2004. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci 24:8009-8018.
4. Chao M, Casaccia-Bonnefil P, Carter B, Chittka A, Kong H, Yoon SO. 1998. Neurotrophin receptors: Mediators of life and death. Brain Res Rev 26:295-301.
5. Chao M, Hempstead BL. 1995. p75 and Trk: A two-receptor system. Trends Neurosci 18:321-326.
6. Chaudhary P, Ahmed F, Quebada P, Sharma SC. 1999. Caspase inhibitors block the retinal ganglion cell death following optic nerve transection. Brain Res Mol Brain Res 67:36-45.
7. Deshmukh M, Johnson EM Jr. 1997. Programmed cell death in neurons: Focus on the pathway of nerve growth factor deprivation-induced death of sympathetic neurons. Mol Pharmacol 51:897-906.
8. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aquayo AJ. 1998. Prolonged delivery of brain derived neurotrophic factor by adenovirus-infected Muller cells temporaly res-cues injured retinal ganglion cells. Proc Natl Acad Sci USA 95:3978-3983.
9. Farkas RH, Grosskreutz CL. 2001. Apoptosis, neuroprotection, and retinal ganglion cell death: An overview. Int Ophthalmol Clin 41:111-130.
10. Fortune B, Bui BV, Morrison JC, Johnson EC, Dong J, Cepurna WO, Jia L, et al. 2004. Selective ganglion cell functional loss in rats with experimental glaucoma. Invest Ophthalmol Vis Sci 45:1854-1862.
11. Friedman DS, Cramer J, Quigley H. 2005. A more proactive approach is needed in glaucoma care. Arch Ophthalmol 123:1134-1135.
12. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma S. 1995. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 61:33-44.
13. Hart WM Jr, Becker B. 1982. The onset and evolution of glaucomatous visual field defects. Ophthalmology 89:268-279.
14. Hartwick AT. 2001. Beyond intraocular pressure: Neuroprotective strategies for future glaucoma therapy. Optom Vis Sci 78:85-94.
15. Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. 2000. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci 41:431-442.
16. Kaplan DR, Stephens RM. 1994. Neurotrophin signal transduction by the Trk receptor. J Neurobiol 25:1404-1417.
17. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. 1997. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 115:1031-1035.
18. Ko M, Hu D, Ritch R, SC S. 2000. The combined effect of BDNF and a free radical scavanger in experimental glaucoma. Invest Ophtalmol Vis Sci 41:2967-2971.
19. Kwon YH, Kim YI, Pereira ML, Montague PR, Zimmerman MB, Alward WL. 2003. Rate of optic disc cup progression in treated primary open-angle glaucoma. J Glaucoma 12:409-416.
20. Lambiase A, Centofanti M, Micera A, Manni GL, Mattei E, De Gregorio A, de Feo G, et al. 1997. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefes Arch Clin Exp Ophthalmol 235:780-785.
21. Laquis S, Chaudhary P, Sharma S. 1998. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 784:100-104.
22. Lebrun-Julien F, Saragovi HU, Di Polo A. 2006. Small molecule peptidomimetic ligands of TrkA and p75 neurotrophin receptors promote survival of injured retinal ganglion cells in vivo. Invest Ophthalmol Vis Sci (ARVO Suppl) 47:4808.
23. LeSauteur L, Wei L, Gibbs B, Saragovi HU. 1995. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. J Biol Chem 270: 6564-6569.
24. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. 2003. Factors for glaucoma progression and the effect of treatment: The early manifest glaucomal trial. Arch Ophthalmol 121:48-56.
25. Lewin GR, Barde Y-A. 1996. Physiology of the Neurotrophins. Annu Rev Neurosci 19:289-317.
26. Li S, Saragovi HU, Nedev H, Zhao C, Racine RJ, Fahnestock M. 2005. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Mol Cell Neurosci 29:162-172.
27. Lipton SA. 2001. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res 131:712-718.
28. Longo FM, Manthorpe M, Xie YM, Varon S. 1997. Synthetic NGF peptide derivatives prevent neuronal death via a p75 receptor-dependent mechanism. J Neurosci Res 48:1-17.
29. Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, Saragovi HU. 2000. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol Pharmacol 57:385-391.
30. Maliartchouk S, Saragovi HU. 1997. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. J Neurosci 17:6031-6037.
31. McCarthy MJ, Rubin LL, Philpott KL. 1997. Involvement of caspases in sympathetic neuron apoptosis. J Cell Sci 110:2165-2173.
32. Michel PP, Lambeng N, Ruberg M. 1999. Neuropharmacologic aspects of apoptosis: Significance for neurodegenerative diseases. Clin Neuropharmacol 22:137-150.
33. Moore C, Epley D, Milne S, Morrison J. 1995. Long-term noninvasive measurement of intraocular pressure in the rat eye. Curr Eye Res 14:711-717.
34. Moore C, Milne S, Morrison J. 1993. Noninvasive measurement of rat intraocular pressure with the Tonopen. Invest Ophthalmol Vis Sci 34:363-369.
35. Morrison J, Nylander K, Lauer A, Cepurna W, Johnson E. 1998. Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma. Invest Ophthalmol Vis Sci 39:526-531.
36. O'Brien C, Schwartz B, Takamoto T, Wu DC. 1991. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 111:491-500.
37. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. 2000. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 41:764-774.
38. Quigley HA, Addicks EM, Green WR. 1982. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol 100:135-146.
39. Rudzinski M, Saragovi HU. 2005. Glaucoma: Validated and facile in vivo experimental models of a chronic neurodegenerative disease for drug development. Curr Med Chem 5:43-49.
40. Rudzinski M, Wong TP, Saragovi HU. 2004. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol 58:341-354.
41. Saragovi HU, Burgess K. 1999. Small molecule and protein-based neurotrophic ligands: Agonists and antagonists as therapeutic agents. Exp Opin Ther Patients 9:737-751.
42. Saragovi HU, Gehring K. 2000. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends Pharmacol Sci 21:93-98.
43. von Bartheld CS, Byers MR, Williams R, Bothwell M. 1996. Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system. Nature 379:830-833.
44. Wirt H, Draeger J, Rumberger E, Deutsch C, Dauper J. 1989. Comparative studies of the calibration of new electronic automatic tonometers. Fortschr Ophthalmol 86:403-406.
45. Zaccaro M, Ivanisevic L, Perez P, Meakin S, Saragovi H. 2001. p75 co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. J Biol Chem 276:31023-31029.